A new drug called baxdrostat is making waves in the medical world. In a recent study, it significantly lowered blood pressure and improved markers of kidney health in patients with chronic kidney disease (CKD) and uncontrolled hypertension.
These early results are promising — and with Phase 3 trials underway, researchers are hopeful this could be a breakthrough for people dealing with two life-threatening conditions at once.
Table of Contents
Background
Chronic kidney disease and high blood pressure are tightly connected. One often worsens the other, creating a dangerous loop that can lead to heart attacks, strokes, kidney failure, and other serious complications.
A key player in this link is aldosterone, a hormone made by your adrenal glands. It causes your body to hold onto salt and water, which raises blood pressure. When aldosterone levels remain high over time, it can lead to stiff blood vessels, heart damage, and scarring in the kidneys.
Baxdrostat targets this hormone, blocking its production. That makes it an exciting candidate for treating both high blood pressure and kidney disease — two conditions that often appear together and worsen each other.
Trial
This new study, presented at the American Heart Association’s Hypertension Scientific Sessions 2025 and published in the Journal of the American Society of Nephrology, focused on patients who were already taking standard treatment for high blood pressure — either ACE inhibitors or ARBs — but still had uncontrolled blood pressure.
Participants had an average systolic blood pressure of 151 mm Hg and signs of significant kidney damage, including high levels of albumin in their urine (around 714 mg/g creatinine) and low glomerular filtration rates (average eGFR of 44 mL/min/1.73 m²).
Design
Researchers enrolled 195 adults, mostly in their mid-60s. The group included 32% women and 40% non-Hispanic white participants. Most of them — about 80% — also had Type 2 diabetes, a common cause of both kidney and heart issues.
Out of these, 192 were randomized into three groups:
| Group | Initial Dose | Increased Dose |
|---|---|---|
| Low-Dose Baxdrostat | 0.5 mg/day | 1 mg/day |
| High-Dose Baxdrostat | 2 mg/day | 4 mg/day |
| Placebo | — | — |
After 26 weeks of treatment, the results were measured and compared.
Results
The blood pressure results were striking. Those taking baxdrostat had a drop in systolic blood pressure that was 8.1 mm Hg greater than the placebo group — about a 5% overall reduction.
But that’s not all:
- Urine albumin levels dropped by 55% in those taking baxdrostat, suggesting better kidney protection.
- Elevated potassium — a common side effect of this type of medication — was reported in 41% of people taking baxdrostat, but most cases were mild.
- There were no deaths or unexpected safety problems.
- Serious side effects were seen in 9% of those on baxdrostat versus 3% on placebo.
These improvements are meaningful. Lowering urine albumin levels is especially important because it predicts kidney damage and heart disease risk. Fewer proteins in the urine means healthier kidneys and better long-term outcomes.
Safety
One concern with aldosterone blockers is the risk of high potassium, which can be dangerous if not monitored. In this study, while the rate of elevated potassium was higher in the baxdrostat group, most cases were not severe, and no major complications were reported.
That said, monitoring will be key for patients using this medication if it becomes widely available.
Significance
Experts say this drug could change how doctors treat hypertension in people with chronic kidney disease. Until now, this group has often been excluded from clinical trials. That’s why these results — based entirely on patients with CKD — are so encouraging.
Dr. Jordana B. Cohen, a kidney and hypertension expert who was not part of the study, noted that these results show real potential for kidney and heart protection. “This medication class could be a game changer,” she said.
Next Steps
These results are just the beginning. The drug is now being tested in larger Phase 3 trials to determine if it can actually delay kidney failure over time. If successful, baxdrostat could become a critical new tool in fighting both hypertension and chronic kidney disease.
Currently, the drug is not yet approved by the FDA. But if the next trials confirm its benefits, baxdrostat could offer hope to millions of people living with these high-risk conditions.
FAQs
What is baxdrostat used for?
It helps lower blood pressure and protect kidney function.
Is baxdrostat FDA-approved?
Not yet. It’s currently in Phase 3 clinical trials.
What does aldosterone do?
It raises blood pressure by causing salt and water retention.
Are there side effects?
Yes, mainly elevated potassium, but most cases were mild.
Does baxdrostat help kidneys?
Yes, it reduced protein in urine, a sign of kidney improvement.
